期刊文献+

成本效用分析文献中效用值的来源分析 被引量:3

The analysis of sources of utility value in cost-utility analysis literature
下载PDF
导出
摘要 使用"健康效用"、"成本效用"、"质量调整生命年"等检索词在中国期刊全文数据库、万方医学数据库和Pub Med检索相关文献,分析其中的效用值来源情况。结果显示:143篇符合条件的文献中,只有68篇文献的效用值来源有效;效用值来源无效的最常见原因是使用了非效用量表的测量结果,其次是效用值错误和不规范引用,少量文献甚至没有交待效用值。可见,成本效用分析文献的质量和数量都亟需提高。 The source of the utility value was analyzed by using the retrieve relevant search terms of "health utility", "cost effectiveness", "quality-adjusted life years" in the Chinese periodical database of full text (CNKI), the medical database of all places and PubMed. The results showed that source utility value from 68 documents were valid in 143 qualified literatures. Using the results of the measurement of non-utility scale was the most common cause of invalid source utility value. Utility value errors and irregularities cited were another reasons. A small amount of literature didn't use the utility value. So, quality and quantity of cost-utility analysis of literature were to be in need of enhancement.
出处 《卫生经济研究》 北大核心 2016年第8期52-54,共3页
关键词 成本效用分析 效用值来源 效用值测量工具 文献 cost-utility analysis sources of utihty value utility value measurement tools literature
  • 相关文献

参考文献4

  • 1Azuma MK, Ikeda S. Investigation of Evidence Sources for Health-Related Quality of Life in Cost-Utility Analysis of Pharmaceuticals in Japan[J]. Value in Health Regional Issues,2014,(3) : 190-196.
  • 2<中国药物经济学评价指南>课题组,刘国恩,胡善联,吴久鸿.中国药物经济学评价指南(2011版)[J].中国药物经济学,2011(3):6-48. 被引量:286
  • 3Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer[J]. Health Qual Life Outcomes, 2008,(6):84.
  • 4Carlson J J, Garrison LP, Ramsey SD, Veenstra DL. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer[J]. Value Health,2009,12(1):20-27.

二级参考文献70

  • 1李幼平.药物经济学与循证医学[J].中国药物经济学,2008,0(6):14-19. 被引量:5
  • 2王施益,李洪超.对我国高校药物经济学教育开展情况的调查[J].中国药物经济学,2008,3(4):49-61. 被引量:11
  • 3杨莉,胡善联,陈文.成本效果比五种可信区间估计法比较[J].中国卫生统计,2004,21(3):150-153. 被引量:5
  • 4F.兰迪.瓦要伯格.应用药物经济学[M].俞雄,周琦奕,陈扬,林峰,译.北京:化学工业出版社,2010.
  • 5国家卫生部.2010中国卫生统计年鉴.http://www.inch.gov.on/publicfiles/business/htmlfiles/zwgkzt/ptjnj/year201O/index2010html.
  • 6刘国恩,胡善联,关志强,吴久鸿,吴晶.药学学科发展报告(2008-2009):药物经济学学科发展.中国科学技术出版社[M].2009:119-131.
  • 7孙利华.药物经济学[M].第二版.北京:中国医药科技出版社-2010.
  • 8Agro KE, Bradley CA, Mittmann N, et al. Sensitivity Analysis in Health Economic and Pharmacoeconomic Studies: Appraisal of the Literature [J]. Pharmacoeconomics 1997; 11 (1): 75-88.
  • 9Anonymous. Consensus conference on guidelines on economic modeling in health technology assessment. Decision analytic modeling in the economic evaluation of health technologies: Aconsensus statement [J]. Pharmacoeconomics 2000; 17 (5): 443-4.
  • 10Backhouse ME. Use of randomized controlled trials for producing cost-effectiveness evidence: Potential impact of design choices on sample size and study duration [J]. Pharmacoeconomics 2002; 20 (15): 1061-77.

共引文献285

同被引文献10

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部